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In contrast to expanded-spectrum cephalosporins, beta-lactam–beta-lactamase inhibitor combinations such
as piperacillin-tazobactam have rarely been associated with vancomycin-resistant Enterococcus (VRE) coloni-
zation and infection. In mice, piperacillin-tazobactam has sufficient antienterococcal activity to inhibit the
establishment of colonization during treatment, but this effect has not been confirmed in human patients. We
prospectively evaluated the acquisition of rectal colonization by VRE among intensive care unit patients
receiving antibiotic regimens containing piperacillin-tazobactam versus those receiving cefepime, an expanded-
spectrum cephalosporin with minimal antienterococcal activity. Rectal swabs were obtained weekly and were
cultured for VRE. For 146 patients with a negative rectal swab for VRE prior to therapy, there was no
significant difference in the frequency of VRE acquisition between patients receiving piperacillin-tazobactam-
and cefepime-containing regimens (19/72 [26.4%] and 23/74 [31.1%], respectively; P 0.28). Of the 19 patients
who acquired VRE in association with piperacillin-tazobactam, 10 (53%) developed the new detection of VRE
during therapy. Patients initiated on treatment with cefepime-containing regimens were significantly more
likely than those initiated on treatment with piperacillin-tazobactam-containing regimens to have received
antibiotic therapy in the prior 30 days (55/74 [74.3%] and 22/72 [30.6%], respectively; P < 0.001). These
findings suggest that piperacillin-tazobactam- and cefepime-containing antibiotic regimens may be associated
with the frequent acquisition of VRE in real-world intensive care unit settings. Although piperacillin-tazobac-
tam inhibits the establishment of VRE colonization in mice when exposure occurs during treatment, our data
suggest that this agent may not prevent the acquisition of VRE in patients.
Antibiotics play a crucial role in the pathogenesis of vanco-
mycin-resistant Enterococcus (VRE) intestinal colonization (6,
7). Studies performed with mouse models suggest that the
effect of antibiotics on colonization represents a balance be-
tween promotion due to the suppression of anaerobes that
compete with VRE and inhibition due to antimicrobial activity
against VRE strains (7, 16). Antibiotics that do not disrupt the
anaerobic microflora (e.g., cefepime and aztreonam) do not
promote VRE colonization in mouse models (7). Antibiotics
that disrupt the anaerobic microflora and that possess minimal
antienterococcal activity (e.g., ceftriaxone, with an MIC of
10,000 g/ml for the VRE test strain used in mouse models)
promote colonization (7). Antibiotics that are active against
anaerobes, that have relatively enhanced antienterococcal ac-
tivity, and that are excreted in high concentrations in bile (e.g.,
piperacillin-tazobactam, with an MIC of 625 g/ml for the
VRE test strain) may inhibit the establishment of VRE colo-
nization during treatment (7, 16). However, piperacillin-ta-
zobactam may also promote the establishment of colonization
when exposure to VRE occurs after treatment and prior to
recovery of the anaerobic microflora (7, 16). In addition, once
VRE colonization is established, piperacillin-tazobactam and
ampicillin-sulbactam promote persistent overgrowth in mice
and in colonized human patients (6, 7, 16).
Because expanded-spectrum cephalosporins have frequently
been associated with colonization with VRE, formulary mod-
ifications that involve restrictions on the use of these agents
have been suggested as control measures. However, the opti-
mal agents that might be substituted for expanded-spectrum
cephalosporins as a means of limiting colonization with VRE
are unknown. Beta-lactam–beta-lactamase inhibitor combina-
tions such as piperacillin-tazobactam have often been chosen
as substitutes for expanded-spectrum cephalosporins because
they have rarely been associated with VRE in clinical studies
and because they inhibit the establishment of colonization in
mice (2, 6, 7, 8, 9, 13–15). Such formulary substitutions have
been associated with reductions in colonization with VRE in
some but not all published studies (2, 8, 9, 11, 13, 14). As noted
above, however, beta-lactam–beta-lactamase inhibitor combi-
nations may promote colonization with VRE in some circum-
stances (7, 16). In addition, it has not been confirmed that
agents such as piperacillin-tazobactam inhibit the establish-
ment of colonization with VRE during treatment in humans.
Agents that do not disrupt intestinal anaerobes (e.g., cefepime
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and aztreonam) offer another alternative to expanded-spec-
trum cephalosporins that alter anaerobic microflora; however,
the potential advantage of these agents may not be realized in
clinical settings, in which they are frequently administered in
combination or in sequence with other agents that may pro-
mote colonization with VRE.
In this study, we compared the frequency of acquisition of
rectal colonization with VRE among intensive care unit (ICU)
patients receiving cefepime-containing antibiotic regimens ver-
sus those receiving piperacillin-tazobactam-containing antibi-
otic regimens. Other expanded-spectrum cephalosporins were
not included as a comparison group because these agents are
rarely used in the study units. Our goal was to evaluate the
acquisition of VRE in a real-world setting in which the antibi-
otics of interest might often be given in sequence or in com-
bination with other antimicrobials. We hypothesized that
piperacillin-tazobactam-containing regimens might be associ-
ated with lower rates of acquisition of VRE in such settings
because the inhibitory activity of piperacillin against VRE
would be maintained, despite the disruption of the indigenous
microflora by other agents. Because piperacillin-tazobactam
inhibits the establishment of colonization with VRE during
treatment in mice, we hypothesized that the acquisition of
colonization with VRE would be particularly uncommon dur-
ing the course of therapy with this agent. Finally, we also
examined the frequency of persistence of colonization with
VRE among patients with positive rectal swab cultures for
VRE prior to the initiation of therapy.
MATERIALS AND METHODS
Setting and study design. The University of Pittsburgh Medical Center is an
800-bed tertiary-care referral center and a level 1 trauma center. VRE has been
endemic in the medical center since the early 1990s. There are approximately 120
ICU beds spread among several ICUs. Consecutive patients in these ICUs who
had commenced with treatment with either piperacillin-tazobactam or cefepime
were assessed for the new detection of stool colonization with VRE as a quality
assurance project of the hospital’s antibiotic management program. In these
ICUs, piperacillin-tazobactam and cefepime were the two most widely used
beta-lactam antibiotics with antipseudomonal activities. Rectal swabs were ob-
tained on a weekly basis from patients in each ICU and were cultured for VRE
as part of routine infection control surveillance efforts.
The prior use of any antibiotic that was administered in the 30 days before the
piperacillin-tazobactam or cefepime course was assessed. Patients who had re-
ceived either piperacillin-tazobactam or cefepime in this 30-day period were
excluded from further analysis. Prior therapy was defined as that which included
antibiotics with activities against anaerobic organisms if it comprised therapy
with metronidazole, clindamycin, ticarcillin-clavulanate, imipenem, meropenem,
ertapenem, amoxicillin-clavulanate, or ampicillin-sulbactam (6).
The demographic details collected from all patients included age, gender, the
length of hospital stay, the length of ICU stay before the patient received the
course of piperacillin-tazobactam or cefepime, and the particular ICU in which
the patient was accommodated. Infection types were defined as pneumonia,
urinary tract infections, wound infections, intra-abdominal infections, and blood-
stream infections, according to Centers for Disease Control and Prevention
definitions. Information regarding the isolation of VRE from clinical cultures
was obtained by a review of the Microbiology Laboratory records.
Patients were defined as acquiring rectal carriage of VRE if they were negative
for VRE by analysis of rectal swabs before they received piperacillin-tazobactam-
or cefepime-containing antibiotic regimens and if their rectal swabs became
positive during the 30 days or in the 30 days after the initiation of this antibiotic
therapy. For patients treated with piperacillin-tazobactam, we assessed whether
the acquisition of VRE occurred during or after therapy because this agent
inhibits the establishment of colonization during treatment in mice. For patients
with positive cultures for VRE before they received piperacillin-tazobactam or
cefepime, we assessed whether colonization persisted during and after the com-
pletion of treatment. Patients were excluded from the assessment of VRE ac-
quisition or persistence only if they died or were discharged from the hospital.
Microbiologic analysis. In order to screen for VRE, rectal swabs were plated
onto Enterococcosel agar containing vancomycin (6 g/ml). Identification and
susceptibility testing were performed in accordance with the guidelines of the
Clinical and Laboratory Standards Institute (formerly NCCLS) (10). Isolates of
Enterococcus gallinarum and E. casseliflavus, species that are intrinsically resis-
tant to low concentrations of vancomycin, were not included. Additional identi-
fication of the Enterococcus species to distinguish E. faecium from E. faecalis or
other species was not routinely performed by the Microbiology Laboratory.
Statistical analysis. Data were analyzed by using SPSS software, version 10.0
(SPSS). Bivariate analyses were performed to compare the baseline character-
istics of the cefepime- and piperacillin-tazobactam-treated patients who were
evaluated for the new detection of VRE rectal colonization. Continuous data
were analyzed by Student’s unpaired t tests. Categorical data were analyzed by
the Pearson chi-square test or Fisher’s exact test. On the basis of previous
infection control data, we estimated that 20% of the patients with negative
initial cultures would acquire colonization with VRE during their ICU admis-
sion. A power calculation indicated that the inclusion of 70 patients per group
would provide a 77% power to detect a clinically significant reduction in the rate
of acquisition of VRE, which was defined as a reduction from 20% to 5%.
RESULTS
Patient characteristics. Four-hundred seventy patients com-
menced on piperacillin-tazobactam or cefepime were assessed
(235 patients received piperacillin-tazobactam and 235 pa-
tients received cefepime). Of these, 29 patients who received
piperacillin-tazobactam and 44 patients who received cefepime
had received either piperacillin-tazobactam or cefepime in the
30 days prior to the initiation of the study antibiotic treatment
in the ICU and so were excluded from further analysis. Of the
remaining 397 patients, 52 (13%) were colonized with VRE
before they began therapy with cefepime or piperacillin-ta-
zobactam. Of these 397 patients, 146 were eligible for the
analysis of VRE acquisition because they had a rectal swab
negative for VRE before they commenced piperacillin-ta-
zobactam (72 patients) or cefepime (74 patients) therapy and
had a follow-up rectal swab analysis performed in the 30 days
after antibiotic therapy commenced.
Table 1 shows a comparison of the baseline characteristics of
the 146 cefepime- and piperacillin-tazobactam-treated patients
who were evaluated for the acquisition of VRE. Cefepime-
treated patients had significantly longer prior hospital and ICU
stays and were more likely to have been cared for in the
Cardiothoracic ICU and to have received therapy with the
study antibiotics for pneumonia. Antibiotic therapy was admin-
istered frequently in the 30 days prior to the commencement of
the piperacillin-tazobactam- and cefepime-containing regi-
mens, and the patients in the cefepime group were significantly
more likely to have received prior antibiotic therapy (59/74
[79.7%] and 35/72 [48.6%], respectively; P  0.001).
VRE acquisition. Of the 146 patients assessed for the acqui-
sition of VRE, 42 (28.8%) had the new detection of VRE
rectal colonization. There were no significant differences in the
acquisition of VRE between patients receiving piperacillin-
tazobactam (19/72 patients; 26.4%) and those receiving
cefepime (23/74 patients; 31.1%) (P  0.28) (Table 2). Of the
19 patients who acquired VRE in association with piperacillin-
tazobactam therapy, 10 (53%) developed the new detection of
VRE during the course of piperacillin-tazobactam treatment.
Of the 23 patients who acquired VRE in association with
cefepime therapy, 11 (48%) developed the new detection of
VRE during the course of cefepime therapy. The number of
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swabs collected to assess the acquisition of VRE did not differ
between the piperacillin-tazobactam and the cefepime groups
(2.3  0.4 and 2.5  0.7, respectively; P  0.52).
Persistence of established VRE colonization. Eighteen ad-
ditional patients were eligible for analysis of the effect of an-
tibiotic therapy on the persistence of established colonization
because they had a positive rectal swab culture for VRE before
they commenced piperacillin-tazobactam (8 patients) or
cefepime (10 patients) therapy and had a follow-up rectal swab
performed in the 30 days after antibiotic therapy commenced.
One hundred percent of the cefepime-treated patients contin-
ued to have positive cultures for VRE during or after the
completion of the course of treatment, whereas 88% (seven of
eight) of the piperacillin-tazobactam-treated patients contin-
ued to have positive cultures for VRE (P  0.20).
Isolation of VRE from clinical cultures. Of 397 patients who
had not received therapy with piperacillin-tazobactam or
cefepime in the 30 days prior to the initiation of therapy in the
ICU, 25 (6.3%) had VRE isolated from cultures of clinical
specimens. There was no significant difference in the frequency
of isolation of VRE from clinical specimen cultures between
patients treated with piperacillin-tazobactam (4.9%; 10 of 206)
and those treated with cefepime (7.9%; 15 of 191) (P  0.20).
DISCUSSION
Our findings do not provide support for our hypothesis that
in ICU settings piperacillin-tazobactam-containing antibiotic
regimens may be associated with lower rates of VRE acquisi-
tion than cefepime-containing regimens. There was a nonsig-
nificant increase in the frequency of VRE acquisition in the
cefepime group; however, patients receiving cefepime had sig-
nificantly longer prior hospital and ICU stays and were more
likely to have received antibiotics in the preceding 30 days.
Cefepime-treated patients were more likely than piperacillin-
tazobactam-treated patients to have been cared for in the Car-
diothoracic ICU; however, it is unlikely that this biased the
results in favor of cefepime because the frequency of VRE
acquisition was high for both groups of patients in the unit
(12 of 23 [52%] cefepime-treated patients and 2 of 5 [40%]
piperacillin-tazobactam-treated patients on the unit acquired
colonization with VRE). In fact, we reanalyzed the data after
exclusion of the Cardiothoracic ICU patients and found that
TABLE 1. Comparison of baseline characteristics of 146 ICU patients treated with cefepime and those of patients treated with piperacillin-
tazobactam-containing antibiotic regimens and evaluated for new detection of rectal colonization with VRE
Variable Cefepime (n  74) Piperacillin-tazobactam(n  72) P
Male gender (no. [%]) 43 (58.1) 37 (51.4) 0.20
Age (yr [mean  SD]) 58.9 18.1 61.4  17.5 0.87
Prior no. of days in hospital (mean  SD) 10.2  9.1 5.4  7.1 0.04
Prior no. of days in ICU (mean  SD) 8.0  7.2 3.3  4.5 0.001
Any antibiotic treatment in prior 30 days
(no. [%] of patients)a
59 (79.7) 35 (48.6) 0.001
Vancomycin 38 (51.4) 11 (15.3) 0.001
Expanded-spectrum cephalosporin 4 (5.4) 3 (4.2) 0.73
Fluoroquinolone 30 (40.5) 14 (19.4) 0.005
Agent with activity against anaerobes 42 (56.8) 8 (11.1) 0.001
Clindamycin 3 (4.1) 1 (1.4) 0.32
Infection type (no. [%] of patients)
Pneumonia 31 (41.9) 15 (20.8) 0.008
Urinary tract infection 13 (17.6) 13 (18.1) 1.0
Bloodstream infection 13 (17.6) 7 (9.7) 0.23
ICU type (no. [%] of patients)
Medical 19 (25.7) 27 (37.5) 0.20
Cardiothoracic 23 (31.1) 5 (6.9) 0.001
Neonatal 6 (8.1) 6 (8.3) 0.76
Trauma 5 (6.8) 8 (11.1) 0.84
Coronary care 5 (6.8) 7 (9.7) 0.73
Surgical 4 (5.4) 4 (5.6) 0.98
Other 12 (16.2) 15 (20.8) 0.36
a Clindamycin was a subset of agents with activity against anaerobes. Vancomycin included only patients receiving intravenous therapy.
TABLE 2. Comparison of rates of new detection of colonization
and infection with VRE among 146 ICU patients treated with
cefepime-containing antibiotic regimens and those among
patients treated with piperacillin-tazobactam-containing
antibiotic regimens
Parameter
No. (%) of patients treated with:
PCefepime
(n  74)
Piperacillin-tazobactam
(n  72)
VRE colonization 23 (31.1) 19 (26.4) 0.28
VRE infection 5 (6.8) 4 (5.6) 0.20
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11/51 (22%) cefepime-treated patients versus 17/67 (25%)
piperacillin-tazobactam-treated patients acquired VRE coloni-
zation (P  0.23). Of the patients with known VRE coloniza-
tion prior to the beginning of therapy, the piperacillin-tazobac-
tam- and the cefepime-containing regimens were associated
with persistent positive stool cultures in 88% and 100% of
patients, respectively. These findings demonstrate that both
piperacillin-tazobactam therapy and cefepime therapy may be
associated with the frequent acquisition and persistence of
VRE in real-world ICU settings.
Although piperacillin-tazobactam may inhibit the establish-
ment of colonization with VRE in mice when exposure occurs
during treatment (7, 16), we are aware of only one previous
study that prospectively examined the acquisition of rectal
colonization with VRE during therapy with this agent in pa-
tients. DiNubile et al. (4) found that only 1.6% of piperacillin-
tazobactam-treated patients with intra-abdominal infections
acquired VRE during therapy, whereas 6.4% of ertapenem
recipients with intra-abdominal infections acquired VRE
during therapy. However, because end-of-therapy stool
specimens could be collected up to 3 days after the discon-
tinuation of therapy in that study, it is not possible to assess
whether VRE was acquired during or shortly after the com-
pletion of therapy (4).
Of the 19 patients who acquired VRE in association with
piperacillin-tazobactam therapy in our study, 10 (53%) devel-
oped the new detection of VRE during the course of therapy.
One possible explanation for the discrepancy between our cur-
rent findings and those of previous studies with mouse models
is that some patients may have had low levels of VRE in the
intestinal tract prior to the beginning of piperacillin-tazobac-
tam therapy (i.e., the finding of new positive rectal swab cul-
tures could represent the new detection of colonization due to
the expansion of preexisting VRE populations rather than the
exogenous acquisition of VRE). In fact, we have found that
modification of the previous mouse model (16) to include
orogastric inoculation of 10,000 CFU of VRE 1 day prior to
the beginning of piperacillin-tazobactam therapy results in the
reduced efficacy of the therapy in preventing the establishment
of colonization (50% versus 0% colonization rates for controls
receiving VRE concurrently with the initiation of piperacillin-
tazobactam treatment) (the authors’ unpublished data). Be-
cause rectal swab cultures may have poor sensitivity for the
detection of low-density VRE colonization (lower limit of de-
tection, 4 log10 CFU/g of stool) (3), our current study may
have not detected low levels of VRE present prior to the
initiation of therapy. Also, it is plausible that patients may
repeatedly ingest small numbers of VRE cells while receiving
antibiotic regimens, whereas a single oral inoculum of VRE
has typically been administered in studies with mouse models.
The repeated ingestion of VRE during therapy could po-
tentially increase the risk of acquiring colonization during
piperacillin-tazobactam therapy in mice or in human patients
(12). In addition, some clinical VRE isolates could be more
resistant to inhibition by piperacillin-tazobactam than the
VRE test strain used in the mouse model studies (piperacillin
MIC, 625 g/ml) (7), or relatively low concentrations of
piperacillin could be excreted into the intestinal tracts of pa-
tients in comparison to the concentrations excreted into the
intestinal tracts of mice. In fact, both Nord et al. (11) and
Wilcox et al. (17) have demonstrated significant interpatient
variability in the levels of piperacillin and tazobactam detected
in the stools of patients. Finally, the concurrent use of other
antibiotics in combination with piperacillin-tazobactam may
have reduced the protective effect of this agent in patients.
Although our current and previous findings (6) suggest that
piperacillin-tazobactam therapy may promote VRE coloniza-
tion in patients, this agent has not been associated with VRE
in case-control studies. However, it is notable that many clin-
ical studies either have failed to look for an association be-
tween piperacillin-tazobactam and VRE or have grouped pen-
icillins together for the purposes of analysis. For example, of 14
such studies included in a review of antimicrobial risk factors
for colonization with VRE, 5 (36%) included “penicillins” in
the analysis and 9 (65%) either definitely did not include pen-
icillins in the analysis or provided insufficient details to deter-
mine whether penicillins were included (5). The grouping of
penicillins together is problematic, because these agents differ
significantly in their biliary excretion and in their activities
against enterococci and anaerobic organisms. In addition,
many studies that evaluated antimicrobial risk factors for col-
onization with VRE were conducted prior to the emergence of
piperacillin-tazobactam as a “workhorse” antibiotic in the
United States.
Cefepime is excreted in minimal concentrations into bile and
does not cause a significant disruption of the anaerobic micro-
flora in the stools of healthy humans (1). Because most
cefepime-treated patients who developed the new detection of
colonization with VRE had received therapy with other anti-
biotics in the prior 30 days, it is not possible to determine if
colonization with VRE was promoted by cefepime or by the
other antibiotics. In theory, choosing antibiotics that have a
relatively little effect on the anaerobic microflora of the colon
could be a useful strategy for limiting the spread of VRE (6, 7).
Additional studies are needed to examine the effect of
cefepime (and of other agents that cause a minimal disruption
of the anaerobic microflora) on colonization with VRE in
settings in which this agent is used as monotherapy in patients
who have not recently received antibiotic therapy.
Our study has several limitations. First, we did not precisely
measure the level of adherence to the culture protocol, and we
did not perform a time-dependent analysis of the rate and
timing of VRE acquisition. However, the overall rate of com-
pliance with weekly rectal swab surveillance cultures in the
ICUs during the year of the study was greater than 80% (au-
thors’ unpublished data), and the number of swabs collected to
assess the acquisition of VRE did not differ between the two
groups. Second, because the treatment groups were not ran-
domized, it is possible that there were differences among the
groups, in addition to those discussed above, that might have
affected the risk of acquiring VRE. Finally, the species of the
VRE isolates from the study patients were not determined and
the isolates were not subjected to molecular typing, so we
cannot exclude the possibility that clonal outbreaks were oc-
curring in some of the ICUs. However, a hospital-wide culture
survey in 2000 demonstrated that 95% of the VRE isolates
were E. faecium and six distinct clones were identified by
pulsed-field gel electrophoresis (PFGE). On the basis of the
infection control records, no significant increases in the rates of
VRE colonization or infection were noted in the ICUs during the
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study period. In addition, PFGE of 18 VRE isolates from the
Cardiothoracic ICU at the time of the study demonstrated the
presence of five distinct PFGE clones.
In summary, the rate of new detection of VRE rectal colo-
nization did not differ significantly among ICU patients receiv-
ing piperacillin-tazobactam versus those receiving cefepime-
containing antibiotic regimens. The new detection of VRE in
association with piperacillin-tazobactam therapy frequently oc-
curred during the course of therapy, suggesting that this agent
may not inhibit the exogenous acquisition of VRE in patients.
However, additional studies by the use of broth enrichment
cultures or PCR are needed to exclude the possibility that
piperacillin-tazobactam therapy caused the expansion of pre-
existing VRE populations that were not detected by using
rectal swabs. Although formulary substitutions of piperacillin-
tazobactam or cefepime for expanded-spectrum cephalospo-
rins offer a potential strategy for controlling colonization with
VRE, our data suggest that neither of these agents is likely to
provide a panacea for the control of this important nosocomial
pathogen.
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